article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

For example, transcriptomic processes are showing the potential to identify and track failures in gene expression and gene regulation of amyloid and tau-related biomarkers, understood as precursors to the onset of Alzheimers disease (AD). Clinical Pharmacology and Therapeutics. Clinical Pharmacology and Therapeutics.

article thumbnail

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development

Alta Sciences

Beyond bioanalysis, understanding the mechanism of action is equally important, as different classes of oligonucleotidessuch as antisense oligonucleotides (ASOs)interact with mRNA in distinct ways to regulate gene expression. Our experts stay up to date on all new and evolving regulations to guarantee regulatory compliance in your studies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

Clinical Pharmacology & Therapeutics , 111(3), 531538. Pharmaceutical Regulations in Japan 2020. Journal of Clinical Pharmacology , 51(3), 531538. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. Freyr Solutions.

article thumbnail

Are Gaps in Your Clinical Pharmacology Program Jeopardizing Your Drug’s Approval?

Fierce BioTech

Are Gaps in Your Clinical Pharmacology Program Jeopardizing Your Drug’s Approval? Eva Gil Berglund, PhD Justin Hay, PhD Paola Coppola, MSc Duration 60 Minutes Clinical pharmacology information comprises more than 50% of a drug label. Click here to login. Listing Image Certara-LogoListing-12052023.png

article thumbnail

Clinical Pharmacology Considerations for Peptide Drug Products

thought leadership

The FDA has recently issued this draft guidance to address clinical pharmacology considerations for peptide drug products. These recommendations are within the framework of the existing regulations and reference several existing guidance documents as appropriate for both drugs and biologics.

article thumbnail

Optimized 505(b)(1) and 505(b)(2) Clinical Pharmacology Programs to Accelerate Drug Development

The Premier Consulting Blog

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways. food effect, smoking, and drug-drug interactions) on drug exposure and response.

article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

1 Regulators invest significant consideration balancing quality-of-life measures with overall survival when assessing novel oncology treatments. Translational and Clinical Pharmacology [Internet]. Clinical Pharmacology & Therapeutics. Antibody drug conjugated with cytotoxic payload.